Phase 2 N=51 HIPEC for Peritoneal Carcinomatosis
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=83 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 9.38; 14.7 Months
Phase 1 N=18 Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
Peritoneal Surface Malignancy
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 2 N=18 Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
Pancreatic Cancer
Primary: Response Rate as Measured Per RECIST 1.1 Criteria — 12; 2 Participants
Phase 3 N=30 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Phase 2 N=273 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants
Phase 3 N=861 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Phase 2 N=50 BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Metastatic Pancreatic Cancer
Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months
Phase 2 N=188 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Abdominal Neoplasm · Colonic Neoplasm · Mesothelioma
Primary: Number of Participants With Disease-free Survival
Phase 2 N=21 Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Gynecologic Cancer · Gynecologic Neoplasms · Peritoneal Carcinomatosis
Primary: Proportion of Participants Who Are Successfully Down Staged to Resectable Based on Peritoneal Carcinomatosis Index (PCI) and Principal Investigator (PI) Discretion…
Phase 2 N=40 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Phase 2 N=51 A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
Peritoneal Carcinomatosis
Primary: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by…
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
Phase 2 N=25 Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Stage IV Pancreatic Cancer
Primary: Complete Response Rate — 2; 15; 4; 3 Participants
Phase 2 N=42 Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Primary: 12- Month Overall Survival (OS) — 16 Participants
Phase 2 N=40 Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Maximum Tolerated Dose (MTD) of Epacadostat — 600 mg BID
Phase 2 N=2 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Mesothelioma · Peritoneal Mesothelioma
Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery
Phase 2 N=75 Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
Metastatic Pancreatic Cancer · Pancreatic Cancer
Primary: Progression Free Survival — 54; 97 percentage of participants
Phase 2 N=160 Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
Cancer
Primary: Overall Survival — 8.4; 6.7 months — p=0.352
Phase 2 N=33 Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Number of Participants With Resectability Rate — 15 Participants
Phase 3 N=211 Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival — 6.4; 5.9 months
Phase 2 N=39 Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
Phase 2 N=21 Cabozantinib and Pembrolizumab in Metastatic Pancreas
Pancreatic Cancer
Primary: Progression-free Survival — 2 Participants
Phase 2 N=170 A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Neoplasms · Neoplasm Metastasis · Pancreatic Cancer
Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)
Phase 2 N=27 MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
Pancreatic Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants
Phase 1 N=30 Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants
Phase 2 N=44 Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival — 3.9 months
Phase 2 N=23 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants
Phase 2 N=14 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Neoplasms · Pancreatic Neoplasms
Primary: Objective Response (OR) (Partial Responses + Complete Responses) in Phase 2 Subjects of Short Infusion LMB-100+ Nab-paclitaxel — 1 Participants